7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
The Serum Institute of India and Bharat Biotech are in talks with the Mexican government for manufacturing vaccines in a deal that will help the two Indian pharmaceutical companies expand their presence in Mexico and the Latin American market. 6 June 2023
As the final sessions of the 2023 congress of the American Society of Clinical Oncology (ASCO) draw to a close, attendees will reflect on a number of significant presentations, from both smaller biotechs and large drugmakers. 6 June 2023
Day One Biopharmaceuticals shares leapt 33.8% to $18.19 in pre-market trading on Monday, after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pre-treated RANO-HGG evaluable patients in pediatric low-grade glioma trial. 6 June 2023
Portuguese neuroscience specialist BIAL has announced positive results from the Phase III EPSILON trial of its innovative Parkinson’s disease therapy Ongentys (opicapone). 6 June 2023
US biotech major Gilead Sciences’ recent investments into oncology - including its $11.9 billion acquisition of Kite Pharma in 2017 - have made the company one of the major players in the oncology space. 6 June 2023
A post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, is to be stopped early. 5 June 2023
Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too. 5 June 2023
Belgium’s largest pharma company UCB today revealed that its developmental treatment for adults with hidradenitis suppurativa (HS) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). 5 June 2023
GLP1 receptor agonists (GLP1RA) are known as diabetes treatments, but recently they have also doubled as the new generation drugs for overweight/obesity. 5 June 2023
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology. 5 June 2023
Both AstraZeneca and Merck & Co have presented data at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) that reflects the ability of their drugs to boost survival in lung cancer. 5 June 2023
French privately held pharma major Servier has presented results from the pivotal Phase III INDIGO clinical trial investigating vorasidenib, showing efficacy in the treatment of low-grade glioma, a difficult to treat form of brain cancer. 5 June 2023
More than three dozen state-level enforcers reached a $102.5 million deal with Indivior to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone (buprenorphine) ahead of a looming September trial. 5 June 2023
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. 5 June 2023
In an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO), Eli Lilly revealed new data for its CD4 and CD6 blocker Verzenio (abemaciclib). 5 June 2023
On June 1, a new unitary patent system came into effect in Europe. The system allows inventions to be protected by a single unitary patent in 17 European Union countries. 5 June 2023
Danish diabetes care giant Novo Nordisk has entered into exclusive negotiations for a controlling stake in France-based Biocorp, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in Biocorp. 5 June 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024